Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy
A Placebo-controlled Study Examining the Morphological/Biochemical Effects of Intrarosa on the Vulvar Vestibule and Vagina in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy
Sponsor: Center for Vulvovaginal Disorders
Listed as NCT03782480, this PHASE3 trial focuses on Dyspareunia and Genitourinary Syndrome of Menopause and remains ongoing. Sponsored by Center for Vulvovaginal Disorders, it has been updated 7 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Feb 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
▶ Show 2 earlier versions
-
Feb 2019 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Center for Vulvovaginal Disorders
- EndoCeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .